Page 185 - Read Online

Cui et al. Diagnosis and treatment of meningeal carcinomatosis

RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, solid tumors: exclusion of intra-CSF chemotherapy does not affect
Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, 2nd, Vick NA, treatment outcome. Comparison of two prospective series. Neurology
Paleologos N, Fredericks RK, Schold SC Jr, Bigner DD. Intrathecal 1997;48:1029.
131I-labeled antitenascin monoclonal antibody 81C6 treatment of 93. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to
patients with leptomeningeal neoplasms or primary brain tumor non-small cell lung cancer: combined modality therapy. Arch Neurol
resection cavities with subarachnoid communication: phase I trial 1998;55:506-12.
results. Clin Cancer Res 1996;2:963-72. 94. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit
76. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter M. Prognostic factors and treatment options in patients with
I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system leptomeningeal metastases of different primary tumors: a retrospective
metastases in women who receive trastuzumab-based therapy for analysis. J Cancer Res Clin Oncol 2010;136:1729-35.
metastatic breast carcinoma. Cancer 2003;97:2972-7. 95. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe
77. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J. Breast H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga
cancer subtypes and survival in patients with brain metastases. Breast S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa
Cancer Res 2008;10:R20. H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or
78. Park IH, Kwon Y, Ro JY, Lee KS, Ro J. Concordant HER2 status chemotherapy for non-small-cell lung cancer with mutated EGFR. N
between metastatic breast cancer cells in CSF and primary breast Engl J Med 2010;362:2380-8.
cancer tissue. Breast Cancer Res Treat 2010;123:125-8. 96. Lee DW, Shin DY, Kim JW, Keam B, Kim TM, Kim HJ, Kim DW,
79. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Wu HG, Paek SH, Kim YW, Heo DS, Kim DG, Lee SH. Additional
Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal prognostic role of EGFR activating mutations in lung adenocarcinoma
fluid is altered in HER2-positive breast cancer patients with brain patients with brain metastasis: integrating with lung specific GPA
metastases and impairment of blood-brain barrier. Anticancer Drugs score. Lung Cancer 2014;86:363-8.
2007;18:23-8. 97. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY,
80. Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Yu CJ, Yang JC. Epidermal growth factor receptor tyrosine kinase
Lassig D, Schoenberg S, Heinemann V. Application of intrathecal inhibitors for non-small-cell lung cancer patients with leptomeningeal
trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis. J Thorac Oncol 2015;10:1754-61.
carcinomatosis in HER2-overexpressing metastatic breast cancer. 98. Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y,
Oncol Rep 2006;15:1373-7. Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M. Cerebrospinal
81. Hofer S, Mengele K, Stemmler HJ, Schmitt M, Pestalozzi B. fluid concentration of gefitinib and erlotinib in patients with non-small
Intrathecal trastuzumab: dose matters. Acta Oncol 2012;51:955-6. cell lung cancer. Cancer Chemother Pharmacol 2012;70:399-405.
82. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose 99. Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK,
intrathecal trastuzumab for leptomeningeal metastases secondary to Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson
HER-2 overexpressing breast cancer. Ann Oncol 2008;19:1978-80. BE, Kesari S. A phase I trial of high dose gefitinib for patients
83. Groves MD. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases from non-small cell lung cancer.
with leptomeningeal metastases. Neurology 2006;66:1609-10; author Oncotarget 2015;6:4527-36.
reply 1609-10. 100. Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.
84. Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis
Voest EE, Geurts-Moespot A, Visser MC, Taphoorn MJ. CSF levels in non-small-cell lung cancer. J Thorac Oncol 2013;8:1069-74.
of angiogenesis-related proteins in patients with leptomeningeal 101. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schutz
metastases. Neurology 2005;65:1120-2. M, Serke M, Stohlmacher-Williams J, Marten A, Maria Huber R,
85. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr Dickgreber NJ. Efficacy of the irreversible ErbB family blocker
UP. Bevacizumab safety in patients with central nervous system afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase
metastases. Clin Cancer Res 2010;16:269-78. inhibitor (TKI)-pretreated non-small-cell lung cancer patients
86. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, with brain metastases or leptomeningeal disease. J Thorac Oncol
Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety 2015;10:156-63.
of bevacizumab in active brain metastases from non-small cell lung 102. Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada T, Mochizuki S, Okada
cancer. J Neurooncol 2010;100:443-7. Y, Nakada M, Murakami T, Yano S. High efficacy of third generation
87. Groves MD. Leptomeningeal disease. Neurosurg Clin N Am EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model
2011;22:67-78, vii. with EGFR-mutant lung cancer cells. Oncotarget 2016;7:3847-56.
88. Brastianos PK, Brastianos HC, Hsu W, Sciubba DM, Kosztowski 103. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T,
T, Tyler BM, Recinos VR, Burger P, Grossman SA. The toxicity Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner
of intrathecal bevacizumab in a rabbit model of leptomeningeal KD, Tursi J, Blackhall F. First-line crizotinib versus chemotherapy in
carcinomatosis. J Neurooncol 2012;106:81-8. ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
89. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: 104. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous
analysis of 31 patients with sustained off-therapy response following system as a sanctuary site in ALK-positive non-small-cell lung cancer.
combined-modality therapy. Neurology 1994;44:1463-9. J Thorac Oncol 2013;8:1570-3.
90. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome 105. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner
in aggressively treated meningeal carcinomatosis. Arch Neurol KD. CSF concentration of the anaplastic lymphoma kinase inhibitor
1994;51:457-61. crizotinib. J Clin Oncol 2011;29:e443-5.
91. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from 106. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge
solid tumors: a comparison of two prospective series treated DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf
with and without intra-cerebrospinal fluid chemotherapy. Cancer J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M,
1998;82:1756-63. Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell
92. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases (LM) in lung cancer. N Engl J Med 2014;370:1189-97.
Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ September 18, 2017 177